ArticleInfection and immunity2015
Control of Mycobacterial Infections in Mice Expressing Human Tumor Necrosis Factor (TNF) but Not Mouse TNF.
Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Applications of humanized mice inMolecular medicine reports · 2026Review
- Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.Antimicrobial agents and chemotherapy · 2022Article
- TNF hampers intestinal tissue repair in colitis by restricting IL-22 bioavailability.Mucosal immunology · 2022Article
- Transmembrane TNF and Its Receptors TNFR1 and TNFR2 in Mycobacterial Infections.International journal of molecular sciences · 2021Review
- Current Perspectives on the Role of TNF in Hematopoiesis Using Mice With Humanization of TNF/LT System.Frontiers in immunology · 2021Article
- Altered composition and functional profile of high-density lipoprotein in leprosy patients.PLoS neglected tropical diseases · 2020Article
- Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Properties of Fluorescent Far-Red Anti-TNF Nanobodies.Antibodies (Basel, Switzerland) · 2018Article
- Transmembrane TNF and Partially TNFR1 Regulate TNFR2 Expression and Control Inflammation in Mycobacterial-Induced Pleurisy.International journal of molecular sciences · 2018Article
- [Cytokine neutralization at specific cellular source : A new therapeutic paradigm? German Version].Zeitschrift fur Rheumatologie · 2017Article
- Cytokine neutralization at specific cellular source : A new therapeutic paradigm?Zeitschrift fur Rheumatologie · 2017Article
- Animal Models for Tuberculosis in Translational and Precision Medicine.Frontiers in microbiology · 2017Review
- VHH-Based Bispecific Antibodies Targeting Cytokine Production.Frontiers in immunology · 2017Article
- Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Innate myeloid cell TNFR1 mediates first line defence against primary Mycobacterium tuberculosis infection.Scientific reports · 2016Article
- TNF Neutralization Results in the Delay of Transplantable Tumor Growth and Reduced MDSC Accumulation.Frontiers in immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor (TNF) is an important cytokine for host defense against pathogens but is also associated with the development of human immunopathologies. TNF blockade effectively ameliorates many chronic inflammatory conditions but compromises host immunity to tuberculosis. The search for novel, more specific human TNF blockers requires the development of a reliable animal model. We used a novel mouse model with complete replacement of the mouse TNF gene by its human ortholog (human TNF [huTNF] knock-in [KI] mice) to determine resistance to Mycobacterium bovis BCG and M. tuberculosis infections and to investigate whether TNF inhibitors in clinical use reduce host immunity. Our results show that macrophages from huTNF KI mice responded to BCG and lipopolysaccharide similarly to wild-type macrophages by NF-κB activation and cytokine production. While TNF-deficient mice rapidly succumbed to mycobacterial infection, huTNF KI mice survived, controlling the bacterial burden and activating bactericidal mechanisms. Administration of TNF-neutralizing biologics disrupted the control of mycobacterial infection in huTNF KI mice, leading to an increased bacterial burden and hyperinflammation. Thus, our findings demonstrate that human TNF can functionally replace murine TNF in vivo, providing mycobacterial resistance that could be compromised by TNF neutralization. This new animal model will be helpful for the testing of specific biologics neutralizing human TNF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.